D
Dariusz Pawlak
Publications - 40
Citations - 1118
Dariusz Pawlak is an academic researcher. The author has contributed to research in topics: Radionuclide therapy & Neuroendocrine tumors. The author has an hindex of 15, co-authored 40 publications receiving 923 citations.
Papers
More filters
Journal ArticleDOI
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
Jolanta Kunikowska,Leszek Królicki,Alicja Hubalewska-Dydejczyk,Renata Mikolajczak,Anna Sowa-Staszczak,Dariusz Pawlak +5 more
TL;DR: Results indicate that therapy with tandem radioisotopes (90Y/177Lu-DOTATATE) provides longer overall survival than with a singleRadioisotope (90 Y/177 Lu) and the safety of both methods is comparable.
Journal ArticleDOI
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study
Jarosław B. Ćwikła,Artur Sankowski,N. Seklecka,John R. Buscombe,Anna Nasierowska-Guttmejer,K.G. Jeziorski,Renata Mikolajczak,Dariusz Pawlak,K. Stepien,Jerzy Walecki +9 more
TL;DR: Standard doses of DOTATATE Y-90 therapy is effective and relatively safe in patients with GEP-NET, however, due to ongoing risk of renal toxicity, careful monitoring of the kidney is recommended.
Journal ArticleDOI
Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs).
Anna Sowa-Staszczak,Dorota Pach,Robert Chrzan,Małgorzata Trofimiuk,Agnieszka Stefańska,Monika Tomaszuk,Maciej Kołodziej,Renata Mikolajczak,Dariusz Pawlak,Alicja Hubalewska-Dydejczyk +9 more
TL;DR: Assessment of the usage of peptide receptor radionuclide therapy (PRRT) as a neoadjuvant treatment, enabling surgical intervention in primary inoperable NETs suggested that not only tumour diameter changes, but also tumour volume and contrast enhancement changes in computed tomography should be taken into consideration in assessment of the response to the therapy.
Journal ArticleDOI
Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma
Leszek Królicki,Frank Bruchertseifer,Jolanta Kunikowska,Henryk Koziara,Bartosz Królicki,Maciej Jakuciński,Dariusz Pawlak,Christos Apostolidis,Saed Mirzadeh,Rafał Rola,Adrian Merlo,Alfred Morgenstern +11 more
TL;DR: Targeted alpha therapy with DOTA-Substance P labeled with the short range alpha emitter 213Bi allows for selective irradiation and killing of tumor cells and may evolve as a promising novel option to treat recurrent GBM.
Journal ArticleDOI
Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue
Leszek Królicki,Frank Bruchertseifer,Jolanta Kunikowska,Henryk Koziara,Bartosz Królicki,Maciej Jakuciński,Dariusz Pawlak,Christos Apostolidis,Saed Mirzadeh,Rafał Rola,Adrian Merlo,Alfred Morgenstern +11 more
TL;DR: Targeted alpha therapy ofsecondary GBM with 213Bi-DOTA-SP is safe and well tolerated and may evolve as a promising novel therapeutic option for secondary GBM.